COMMUNIQUÉS West-GlobeNewswire

HOOKIPA Pharma Announces Completion of Sale of HBV and HIV Assets to Gilead
31/10/2025
NEW YORK and VIENNA, Oct. 31, 2025 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”) today announced the completion of the sale of its assets related to HOOKIPA’s HB-400 program and certain of its assets [...]
Alps Announces Closing of Business Combination with Globalink Investment Inc.
31/10/2025
Alps ordinary shares to list on the Nasdaq under the symbol “ALPS” on October 31, 2025 KUALA LUMPUR, Malaysia and NEWARK, Del., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Alps Group Inc (the “ Company ” or “ Alps Group ”), the [...]
Certara to Participate in Upcoming Investor Conferences
31/10/2025
RADNOR, Pa., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced that Company management will participate in the following investor [...]
Nxera Pharma Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2025
31/10/2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma (“the Company” or “Nxera”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the third quarter and nine [...]
Nxera Pharma Receives a Manufacturing Approval Partial Amendment Regarding the Addition of a Manufacturing Site in Asia for QUVIVIQ® 25 and 50 mg
31/10/2025
Second API manufacturing facility added to ensure supply for patients with insomnia in Japan and for future demand across the Asia-Pacific region Expected to improve profitability through manufacturing cost reductions [...]
Vistin Pharma ASA: Third quarter and YTD 2025 financial results
31/10/2025
Vistin Pharma ASA: Third quarter and YTD 2025 financial results Oslo, Norway, 31 st of October 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the third quarter of 2025. Revenue in the third [...]
Corbus Pharmaceuticals Announces Pricing of Public Offering
31/10/2025
NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an underwritten public [...]
DXS International plc ((AQSE: DXSP) - Final Results
31/10/2025
DXS INTERNATIONAL PLC (AQSE: DXSP) ANNUAL RESULTS for the year ended 30 April 2025 The Board of DXS International plc (“the Company”), the AQSE Growth Market quoted healthcare information and digital clinical decision [...]
NANOBIOTIX annonce un accord stratégique avec HealthCare Royalty pour un montant maximum de 71 millions de dollars et prolonge ainsi son horizon de trésorerie pour une croissance durable
31/10/2025
Les 71 millions de dollars américains permettraient à Nanobiotix d’étendre son horizon de trésorerie jusqu’au début de l’année 2028. Cette opération donne à Nanobiotix la capacité financière de se développer au-delà des [...]
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
31/10/2025
$71 million in funding would extend Nanobiotix cash visibility into early 2028 Transaction enables Nanobiotix development beyond key milestones in head and neck cancer and lung cancer Financing establishes financial [...]
Nxera’s President & CEO to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2025
31/10/2025
Tokyo, Japan and Cambridge, UK, 31 October 2025 – Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces its President & CEO, Chris Cargill, will participate in a ‘Fireside Chat’ at the Jefferies [...]
Unprecedented Clinical data from the Landmark BOOSTB4 Trial to be presented at the 15th International Conference on Osteogenesis Imperfecta in Hong Kong
31/10/2025
COPENHAGEN, Denmark, Oct. 31, 2025 (GLOBE NEWSWIRE) -- BOOST Pharma, a clinical-stage cell biotech company focused on rare skeletal pediatric diseases, is proud to announce that new long-term data from the first-in- [...]
Bavarian Nordic Awarded New Procurement Framework Contract by the European Commission to Strengthen Preparedness Against Smallpox and Mpox
31/10/2025
New and larger framework contract with the European Commission’s Health Emergency Preparedness and Response Authority (HERA) replaces previous agreement and provides for up to 8 million doses of smallpox/mpox vaccine [...]
4DMT Announces Exclusive License Agreement with Otsuka Pharmaceutical Co., Ltd. for Development and Commercialization of 4D-150 in Asia-Pacific
31/10/2025
4DMT to receive $85 million upfront cash payment and expect to receive at least $50 million of cost sharing from Otsuka over the next three years for development activities supporting global registration Up to $336 [...]
InnoCare Announces First Patient Dosed in Clinical Trial of Novel ADC ICP-B794 in China
31/10/2025
BEIJING, Oct. 30, 2025 (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first [...]
Synergy CHC Corp. Announces Third Quarter 2025 Earnings and Conference Call Information
30/10/2025
WESTBROOK, Maine, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ: SNYR) (“Synergy” or the “Company”), a leading consumer health and wellness company, today announced that it plans to release financial [...]
Merit Medical Reports Third Quarter 2025 Results and Updates Full-Year Guidance
30/10/2025
Highlights† Reported revenue of $384.2 million, up 13.0% Constant currency revenue* and constant currency revenue, organic* up 12.5% and up 7.8%, respectively GAAP operating margin of 11.1%, compared to 11.0% in prior [...]
Resmed Inc. Announces Results for the First Quarter of Fiscal Year 2026
30/10/2025
Revenue increased by 9% to $1.3 billion; up 8% on a constant currency basis Gross margin up 290 bps to 61.5%; non-GAAP gross margin up 280 bps to 62.0% Income from operations increased 15%; non-GAAP income from [...]
Stryker reports third quarter 2025 operating results
30/10/2025
Portage, Michigan, Oct. 30, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the third quarter of 2025: Third Quarter Results Reported net sales increased 10.3% to $6.1 billion Organic net [...]

Pages